Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$479M |
| 2 |
Meta Platforms (Facebook)
META
|
+$465M |
| 3 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$445M |
| 4 |
Kenvue
KVUE
|
+$434M |
| 5 |
Micron Technology
MU
|
+$431M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$3.24B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Microsoft
MSFT
|
+$1.56B |
| 4 |
PepsiCo
PEP
|
+$1.34B |
| 5 |
JPMorgan Chase
JPM
|
+$1.34B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.7% |
| 2 | Financials | 7.47% |
| 3 | Consumer Discretionary | 6.7% |
| 4 | Communication Services | 6.02% |
| 5 | Healthcare | 4.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3726
Global X Defense Tech ETF
SHLD
$7.76B
| $562K | ﹤0.01% |
+8,679
| New | +$571K |
|
3727
Farmers & Merchants Bancorp
FMAO
$485M
| $561K | ﹤0.01% |
22,679
+1,839
| +9% | +$45.9K |
|
3728
Maravai LifeSciences
MRVI
$863M
| $560K | ﹤0.01% |
172,281
+5,057
| +3% | +$17K |
|
3729
Savers
SVV
$1.68B
| $560K | ﹤0.01% |
59,909
+5,183
| +9% | +$53.3K |
|
|
SMC
3730
Summit Midstream
SMC
$477M
| $559K | ﹤0.01% |
20,955
+4,508
| +27% | +$107K |
|
3731
Security National Financial
SNFCA
$243M
| $558K | ﹤0.01% |
65,044
+3,850
| +6% | +$31.1K |
|
3732
Byrna Technologies
BYRN
$98.7M
| $557K | ﹤0.01% |
33,199
+5,744
| +21% | +$112K |
|
|
FRMI
3733
Fermi Inc
FRMI
$4.31B
| $556K | ﹤0.01% |
+69,536
| New | +$1.36M |
|
3734
Jack in the Box
JACK
$395M
| $556K | ﹤0.01% |
29,351
-69,901
| -70% | -$1.26M |
|
3735
Innovative Solutions & Support
ISSC
$376M
| $556K | ﹤0.01% |
29,335
+25,363
| +639% | +$289K |
|
3736
Lloyds Banking Group
LYG
$90.1B
| $555K | ﹤0.01% |
104,700
+102,650
| +5,007% | +$497K |
|
|
KLAR
3737
Klarna Group
KLAR
$7.37B
| $554K | ﹤0.01% |
19,147
+16,347
| +584% | +$561K |
|
3738
Red River Bancshares
RRBI
$682M
| $552K | ﹤0.01% |
7,722
-519
| -6% | -$35.5K |
|
3739
Organogenesis Holdings
ORGO
$235M
| $551K | ﹤0.01% |
106,407
+8,697
| +9% | +$42.1K |
|
3740
Inogen
INGN
$155M
| $551K | ﹤0.01% |
81,980
+3,515
| +4% | +$26.4K |
|
|
NAGE
3741
Niagen Bioscience
NAGE
$245M
| $549K | ﹤0.01% |
86,385
+7,802
| +10% | +$54.3K |
|
3742
iShares MSCI All Country Asia ex Japan ETF
AAXJ
$3.85B
| $549K | ﹤0.01% |
5,894
+2,742
| +87% | +$255K |
|
3743
Nathan's Famous
NATH
$398M
| $549K | ﹤0.01% |
5,864
+1,557
| +36% | +$157K |
|
3744
Capital Bancorp
CBNK
$617M
| $548K | ﹤0.01% |
19,449
+2,963
| +18% | +$85K |
|
3745
Achieve Life Sciences
ACHV
$719M
| $547K | ﹤0.01% |
110,032
+110,031
| +11,003,100% | +$480K |
|
|
MITT
3746
TPG Mortgage Investment Trust
MITT
$215M
| $546K | ﹤0.01% |
64,106
+15,867
| +33% | +$124K |
|
3747
Structure Therapeutics
GPCR
$3.76B
| $545K | ﹤0.01% |
7,833
+4,060
| +108% | +$166K |
|
3748
Citizens & Northern Corp
CZNC
$465M
| $544K | ﹤0.01% |
26,947
+774
| +3% | +$15.4K |
|
3749
Hyster-Yale Materials Handling
HY
$629M
| $543K | ﹤0.01% |
18,280
+1,449
| +9% | +$47.8K |
|
3750
Custom Truck One Source
CTOS
$2.43B
| $541K | ﹤0.01% |
93,975
+9,070
| +11% | +$55.4K |
|
Similar funds
Barclays's Q4 2025 Portfolio in Review
As of Q4 2025, Barclays held 5,847 positions worth $417B, down 9.7% from $461B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Barclays withdrew a net $49.1B in Q4 2025, closing 641 positions and reducing 1,715 holdings. Its most notable exit was Verona Pharma, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 20% a quarter earlier, followed by Financials and Consumer Discretionary.
Against the trend, Barclays opened a new position in The Magnum Ice Cream Company N.V. worth $156M.
- Barclays's largest Q4 2025 buy was The Magnum Ice Cream Company N.V.: 9,862,859 shares worth $156M.
- Barclays added most to Gilead Sciences in Q4 2025, an estimated $479M increase.
- Barclays's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $3.24B.
- Barclays fully exited Verona Pharma in Q4 2025, selling an estimated $149M.
- Barclays's ten largest holdings make up 35% of its $417B portfolio in Q4 2025.
- Barclays opened 403 new positions and closed 641 in Q4 2025.
- Barclays's portfolio value fell 9.7% quarter-over-quarter to $417B.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.